L3VLUP
ProSign in

ASND · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ASNDLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ASND
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterASNDLLY
Q3 20209 holders, $4.1bn33 holders, $14.1bn
Q4 202012 holders, $4.5bn29 holders, $17.3bn
Q1 202110 holders, $3.4bn24 holders, $23.0bn
Q2 202110 holders, $3.4bn24 holders, $27.8bn
Q3 202110 holders, $4.5bn31 holders, $29.9bn
Q4 202111 holders, $3.7bn31 holders, $34.7bn
Q1 202210 holders, $3.3bn24 holders, $35.3bn
Q2 20229 holders, $2.5bn33 holders, $42.7bn
Q3 202212 holders, $2.7bn31 holders, $43.4bn
Q4 202212 holders, $3.0bn31 holders, $46.6bn
Q1 20239 holders, $2.6bn33 holders, $44.3bn
Q2 20238 holders, $1.9bn37 holders, $59.6bn
Q3 20238 holders, $2.0bn44 holders, $67.6bn
Q4 202311 holders, $2.8bn45 holders, $73.6bn
Q1 202416 holders, $3.4bn41 holders, $95.3bn
Q2 202414 holders, $2.8bn43 holders, $110bn
Q3 202415 holders, $3.1bn45 holders, $107bn
Q4 202411 holders, $2.6bn46 holders, $93.9bn
Q1 202513 holders, $3.2bn42 holders, $98.4bn
Q2 202511 holders, $3.2bn43 holders, $93.2bn
Q3 202515 holders, $3.7bn39 holders, $86.7bn
Q4 202514 holders, $3.7bn41 holders, $123bn
Q1 202610 holders, $3.1bn39 holders, $106bn
Q2 202612 holders, $4.3bn44 holders, $132bn
ASND

Ascendis Pharma A

Holders
12
Reported value
$4.3bn
Buyers
19
Sellers
9

Breadth +10 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ASND (0)

None.

Only LLY (32)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →